PALATIN TECHNOLOGIES Forum: Community User: CologneFC

Schaut jemand den Livestream und kann berichten? Bin aktuell außer Haus

Vyleesi Presentation sollte dann um 17:40 Uhr sein

BremelanotideResearch Podium Session “Bremelanotide for Hypoactive Sexual Desire Disorder: Contraceptive Subgroups Efficacy Analysis,” Anita Clayton, M.D., University of Virginia; Session M, Friday May 3, 10:40-10:50 am CT

f a c e b o o k

https://www.***.com/pg/ACOGNational/videos/ - Livestream

Sollte man vielleicht mal reinschauen, sobald es was aktuelles von 2019 dort gibt :-)

https://annualmeeting.acog.org/acog-tv/

Perfekt! Danke für's sharen.

Na da lassen wir uns mal überraschen was das bringt. Patente laufen bis 2033 schon mal gut. Wird jedenfalls nochmal für neue Interessenten sorgen.

News incoming

WALTHAM, Mass., May 03, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that it will present new data related to investigational drug bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) and Feraheme® (ferumoxytol) related to iron deficiency anemia (IDA) resulting from abnormal uterine bleeding (AUB) at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting taking place in Nashville, Tennessee from May 3-5. "At ACOG this year we will share new subgroup analyses from our pivotal bremelanotide trials as well as data looking at ferumoxytol in women with AUB," said Julie Krop, M.D., chief medical officer and executive vice president of development at AMAG. “AMAG has a long history of commitment to women’s health, as demonstrated by our broad women’s health portfolio including Intrarosa® and Makena®.” Bremelanotide Research Podium Session “Bremelanotide for Hypoactive Sexual Desire Disorder: Contraceptive Subgroups Efficacy Analysis,” Anita Clayton, M.D., University of Virginia; Session M, Friday May 3, 10:40-10:50 am CT Bremelanotide Research Poster Session “Efficacy of Bremelanotide Across Hypoactive Sexual Desire Disorder Duration Subgroups,” Sheryl A Kingsberg, PhD, University Hospitals Cleveland Medical Center; Session M, Saturday, May 4, 3-4 pm CT Bremelanotide is an investigational drug in development for the treatment of HSDD in pre-menopausal women. HSDD is a condition characterized by low sexual desire that causes marked distress or interpersonal difficulty. Approximately 1 in 10 pre-menopausal women in the United States have HSDD. Feraheme Research Poster Session “Sustained Improvements in Anemia and Fatigue of AUB after a Single Course of Ferumoxytol: 6-month Follow-up,” Naomi V. Dahl, Pharm D, AMAG Pharmaceuticals, Inc. and Anne Moore, DNP, WHNP-BC, FAANP, AMAG Pharmaceuticals, Inc.; Saturday, May 4, 11:30-12:30 pm CT In February of 2018, the U.S. Food and Drug Administration broadened the existing label for ferumoxytol to include all eligible adult IDA patients who have intolerance to oral iron or have had unsatisfactory response to oral iron. Iron deficiency anemia is a common, treatable condition that occurs when iron stores are depleted due to an imbalance between iron uptake and iron utilization. IDA affects an estimated 5 million adults in the United States. Women are generally at greater risk for IDA than men and there are several causes of heavy uterine bleeding that result in low iron levels. About bremelanotide injection Bremelanotide, an investigational product candidate, is being developed for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The PDUFA date for bremelanotide is June 23, 2019. Bremelanotide is designed to be used in anticipation of a sexual encounter, and is thought to possess a novel mechanism of action that impacts the excitatory neural pathways in the brain to restore sexual desire. Bremelanotide has been studied in more than 30 clinical trials with over 2,500 women. AMAG’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was supported by clinical data from two identical large double-blind placebo-controlled Phase 3 studies in which bremelanotide met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured by validated patient-reported outcomes. Women in the trials had the option, after completion of the trial, to continue in an open-label safety extension study for an additional 12 months. Nearly 80% of patients elected to remain in the open-label portion of the study, and all of these patients received bremelanotide. The most common adverse events were nausea, flushing, injection site reactions and headache. The majority of events were reported to be transient and mild-to-moderate in intensity. Bremelanotide is protected by a number of U.S. and foreign patents and applications that are owned by Palatin Technologies, Inc. Certain of the patents include claims directed to the bremelanotide drug composition and methods of use thereof with terms expiring in 2020, and other patents include claims directed to methods of treating female sexual dysfunction by subcutaneous administration of compositions that include bremelanotide with terms expiring in 2033.

https://claytrader.com/stock_chart/PTN/?utm_source=social&utm_medium=stocktwits&utm_campaign=chart

https://www.sec.gov/Archives/edgar/data/792977/000079297719000079/xslF345X03/wf-form4_155674722886204.xml SEC Filling von gestern - AMAG

Ich bin mir sicher dass es ein ausgeprägtes Peak gibt. Natürlich wird es schwierig da dann im passenden Moment die Orders zu setzen.

Ich denke, daher ist auch die AMAG Aktie derzeit verhalten. Wenn Vyleesi mit Labeln zugelassen wird, müssen die trotzdem an Palatin zahlen. Es zählt für Palatin für die Milestone Zahlung nur die Zulassung - mit welchen Auflagen das Medi vertrieben werden darf ist unerheblich.

Aktuell versucht PTN den Widerstand bei 126$ zu überwinden - 2x sind wir daran gescheitert und abgeprallt. Das ist aber ein gutes Zeichen. Es wird weitere Anläufe geben und dann - ohne bad News - werden die 1,26 $ auch überwunden.